BIO-CAT was founded in 1988 by Ed Schuler and his son, Chris and was one of the first wholesalers of dietary enzymes in the United States, and the forerunners in developing formulas for use in digestive preparations. Today, BIO-CAT’s portfolio includes single-to multi-enzyme blends, probiotics, and unique microbial solutions.
By combining expertise in enzymes, microbial technologies, fermentation, and life sciences, the enlarged company is better positioned to accelerate innovation and deliver solutions that address evolving needs across human health, animal nutrition, agriculture, food, and industrial markets, according to a release from BIO-CAT.
“The acquisition will reinforce our presence in the dietary food supplement and health ingredient markets and increase our production footprint and capacity in the USA,” stated Antoine Chagnon, CEO of Lallemand. “This, in turn, should better enable us to meet the requirements of our existing and new customers across the global animal nutrition, agriculture and food industries.”
Lallemand currently operates over 45 yeast, bacteria, and fungi production sites across the world, including facilities in the U.S. The acquisition of BIO-CAT provides two additional sites located in the U.S.: Virginia and Minnesota.
“When my father, Ed Schuler, and I founded BIO-CAT in 1988, we built the company around family values, science, integrity, and lasting relationships,” stated Chris Schuler. “Finding a partner with shared values was just as important as finding one with complementary technologies. Lallemand’s family-owned heritage, long-term vision, and commitment to its people and customers made this a natural fit, and we’re excited about what we’ll accomplish together.”
BIO-CAT acknowledged Jefferies LLC and ArentFox Schiff for guiding the company through this process.
